University of Glasgow
Glasgow, United Kingdom
Location status: Recruiting
NCT Number: NCT06296875
This study aims to determine the mechanisms via which krill oil supplementation increases muscle strength and whether this translates to improvements in gait and functional characteristics in older adults. The studies we will carry out will establish, in healthy older adults, the effects of 6 months of supplementation with krill oil
Objective 1) Muscle structure and function Hypothesis: Krill oil supplementation will increase muscle size and strength alongside positive changes in muscle architecture (pennation angle and fascicle length).
Objective 2) Neuromuscular control and central nervous system (CNS) function Hypothesis: Krill oil supplementation will improve Neuromuscular Junction (NMJ) transmission stability and increase central drive and intramuscular coherence, as a measure of muscle synergy.
Objective 3) Gait and functional characteristics Hypothesis: Krill oil supplementation will improve gait and functional characteristics.
Interested in participating?
Request Info65 year–90 year
All sexes
Interventional
Not applicable
Glasgow, United Kingdom
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
mixed vegetable oil
Krill oil
Other names: (SuperbaBoost)
Time frame: Change from baseline to 24 weeks
We will measure grip strength using a handgrip dynamometer, making 3 maximal contractions in each hand, with the dominant hand recorded. The highest grip strength will be used in analysis.
Time frame: Change from baseline to 24 weeks
We will assess peripheral motor unit (MU) characteristics in the vastus lateralis muscle using intramuscular electromyography
Time frame: Change from baseline to 24 weeks
We will measure gait speed using a gaitrite connected mat during a 4 m walk test and the timed up and go test at usual speed.
Time frame: Change from baseline to 24 weeks
We will measure the muscle strength of the knee extensor muscles during a maximal voluntary contraction (MVC)
Time frame: Change from baseline to 24 weeks
We will measure this using ultrasound
Time frame: Change from baseline to 24 weeks
We will measure this using ultrasound
Time frame: Change from baseline to 24 weeks
We will measure this using ultrasound
Time frame: Change from baseline to 24 weeks
Blood samples (15 ml each visit) will be collected
Time frame: Change from baseline to 24 weeks
During the contractions to measure NMJ transmission instability we will also calculate force steadiness, as a measure of neuromuscular control
Time frame: Change from baseline to 24 weeks
will be measured using High Density surface electromyography (HDsEMG) during submaximal (10%, 30%, 50% and 70% of MVC) and during the MVC
Time frame: Change from baseline to 24 weeks
Motor unit spike train will be measured using the surface electromyography (sEMG) electrodes while participants exert 20% of maximum voluntary contraction
Time frame: Change from baseline to 24 weeks
Intermuscular coherence will be measured for 1 min on 20% of MVC using sEMG electrodes.
Time frame: Change from baseline to 24 weeks
Cortico-muscular coherence is a derived measure, based on measurement of the electroencephalography (EEG) and motor unit spikes. EEG electrodes will be placed over the motor area of hands and worn during hand contractions
Time frame: Change from baseline to 24 weeks
Single stimuli will be delivered to the muscle while participants maintain a 20% MVC isometric contraction, and the intensity of stimulation was increased until a plateau in twitch amplitude and rectus femoris M-wave (Mmax) occurs. Supramaximal stimulation will then be delivered by increasing the final stimulator output intensity by a further 30%.
Time frame: Change from baseline to 24 weeks
Motor evoked potentials (MEPs) will be elicited in the rectus femoris of the dominant leg via single pulse TMS and assessed using electromyographic (EMG) recordings.
Time frame: Change from baseline to 24 weeks
corticomotor inhibition during the MVCs a single TMS stimulation will be delivered over the motor cortex.
Time frame: Change from baseline to 24 weeks
For assessment of corticospinal excitability, participants will maintain a 20% MVC isometric contraction while 20 single TMS pulses, separated by 6 s, will be delivered over the motor cortex
Time frame: Change from baseline to 24 weeks
The 4 m walk test involves participants walking a 4m distance at a normal walking pace, walking through the 4m line at the end of the gaitrite mat. The Timed Up and Go test (timed version of the Get Up and Go test) involves the participant sitting on a chair getting up, walking 3 meters in front of them across the gaitrite mat, returning to the chair and sitting down. The Theia markerless system will be used to extract Gait parameters
Time frame: Change from baseline to 24 weeks
We will also get posture information from the 3D skeleton measurements and balance (pitch and roll) which are important in assessing fall risks and functional gait.
Contact information is provided by the study sponsor or research team.
University of Glasgow
Other
Uncovering the Mechanisms Through Which Krill Oil Increases Muscle Function in Older Adults.
Acronym: KAMM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06329622
Atrophy, Chronic Disease
Shanghai, China
View Trial DetailsNCT07715721
Atrophy, Mental Disorders
Tainan, Taiwan
View Trial DetailsNCT07724587
Atrophy, Muscular Atrophy
Ningbo, China
View Trial DetailsNCT07500376
Atrophy, Bronchial Neoplasms
Samsun, Turkey (Türkiye)
View Trial Details